Teva Pharmaceutical Industries Ltd Hits New 52-Week High at $42.00 (TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)’s share price reached a new 52-week high during mid-day trading on Friday, StockRatingsNetwork.com reports. The stock traded as high as $42.00 and last traded at $41.90, with a volume of 3,762,588 shares traded. The stock had previously closed at $41.57.
TEVA has been the subject of a number of recent research reports. Analysts at RBC Capital initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday. They set a “sector perform” rating and a $39.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday, December 16th. They now have a $42.00 price target on the stock. Finally, analysts at Susquehanna upgraded shares of Teva Pharmaceutical Industries Ltd from a “neutral” rating to a “positive” rating in a research note to investors on Wednesday, November 20th. They now have a $50.00 price target on the stock, up previously from $43.00. Three analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $44.08.
Teva Pharmaceutical Industries Ltd has a 52 week low of $36.26 and a 52 week high of $41.74. The stock has a 50-day moving average of $40.16 and a 200-day moving average of $39.24. The company has a market cap of $35.418 billion and a P/E ratio of 29.50. Teva Pharmaceutical Industries Ltd also saw some unusual options trading activity on Tuesday. Traders acquired 29,553 call options on the stock. This represents an increase of approximately 346% compared to the typical volume of 6,621 call options.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last announced its earnings results on Thursday, October 31st. The company reported $1.27 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.26 by $0.01. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $5.00 billion. During the same quarter in the prior year, the company posted $1.28 earnings per share. The company’s quarterly revenue was up 1.7% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $4.99 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.